Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management
This is a multicentre randomised controlled trial evaluating global health related quality of life outcomes in patients with malignant pleural effusions. Patients will be randomised to receive either chest drain and talc pleurodesis or indwelling pleural catheter and talc pleurodesis. Patients will be followed up for 3 months post intervention
Pleural Effusion, Malignant
DEVICE: Chest Drain Insertion and Talc Pleurodesis|DEVICE: Indwelling Pleural Catheter Insertion and Talc Pleurodesis
Global health-related quality of life, Global health related quality of life as measured by EORTC QLQ-C30, 30 days
Global health-related quality of life, 60 and 90 days|Pleurodesis failure rate, Subsequent pleural intervention required on same side as pleurodesis

Chest X-ray opacification greater than 25% on side of intervention, 30, 60 and 90 days|Improvement in symptoms of pain and breathlessness, Medical Research Council (MRC) dyspnoea scale 100mm Visual Analog Scale for pain and breathlessness, 30, 60 and 90 days|Complication rate, Clinical review and adverse event documentation, Day 7, 14, 30, 60 and 90
This is a multicentre randomised controlled trial evaluating global health related quality of life outcomes in patients with malignant pleural effusions. Patients will be randomised to receive either chest drain and talc pleurodesis or indwelling pleural catheter and talc pleurodesis. Patients will be followed up for 3 months post intervention